ClinicalTrials.gg
RecruitingNCT07441915PDCogTSleepUpdated Apr 30, 2026

Auditory Sleep Stimulation or Sham in People With Parkinson Disease Mild Cognitive Impairment During Cognitive Training

An interventional study of Phase-Targeted Auditory Stimulation (PTAS) and Digital Cognitive Training (CogT) in Parkinson's Disease and Mild Cognitive Impairment, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by University of Zurich · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.

Planned enrollment
18th of 67
50 · median 30
Started
2026
with 4 others
No phase
49 of 85
23 open now
Primary completion
2027-12
later than 23 of 33 live
Registered
81st of 85
by date
Lead sponsor
8 of 85
University of Zurich

Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 18th largest by planned enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2026, is one of 49 with no phase, reaches primary completion later than 23 of the 33 other live ones, and was the 81st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Parkinson Disease with a site in Switzerland, or all of them as a file.
02

Study summary

People with Parkinson's disease are at higher risk of cognitive decline, and current treatments cannot fully prevent this. This study explores non-drug ways to support brain function.

Intervention: Participants will complete a 5-week cognitive training program at home ("brain fitness"). In addition, they will use a sleep device at night that plays soft sounds to improve deep sleep; Half of the participants will actually receive these sounds (auditory stimulation), while the other half will receive a sham (placebo) version - neither the participants nor the researchers will know the group assignment.

Assessments will take place before and after the intervention, and again three months later, including one overnight stay at University Hospital Zurich per assessment.

The goal is to find out whether improving deep sleep can boost the benefits of cognitive training and help slow cognitive decline in Parkinson's disease.

Read the detailed description

Parkinson's disease (PD) is a progressive neurodegenerative disorder associated not only with motor symptoms (such as tremor, slowness of movement, and rigidity), but also with a broad range of non-motor symptoms. Sleep disturbances are common, and many individuals with PD develop cognitive impairment, ranging from mild cognitive impairment (MCI) to dementia. For early cognitive impairment in PD, pharmacological treatment options are limited, and there are currently no established therapies that reliably prevent further cognitive decline. There is therefore a clear need to develop and evaluate non-pharmacological interventions that can support cognitive functioning in this population.

Cognitive training (CogT) is a structured, exercise-based intervention targeting cognitive domains such as attention, memory, and executive functions (e.g., planning and coordination of actions). Evidence supports the efficacy of CogT in PD and in older adults; however, response to training varies considerably between individuals. Sleep-particularly deep sleep-has been proposed as an important factor influencing learning and cognitive performance. Deep sleep is implicated in processes relevant to memory consolidation and daytime cognition. Because sleep disturbances are frequent in PD, impaired sleep may represent a barrier to achieving optimal benefits from CogT.

This study evaluates whether enhancing deep sleep using phase-targeted auditory stimulation (PTAS) can improve the effectiveness of CogT in people with PD and MCI. PTAS is a non-pharmacological method that delivers soft, non-arousing sounds during sleep with the aim of supporting deep sleep. The intervention is administered using a wearable headband device developed at the University of Zurich and ETH Zurich. The device is designed for home use and can be worn during sleep in the participant's own bed. The technology has been used in previous research in younger and older healthy individuals as well as in people with PD, with no relevant side effects reported, and has demonstrated beneficial effects on measures of deep sleep.

Study Design

This is a double-blind, randomized, sham-controlled trial. After eligibility screening, participants are randomly assigned to one of two groups:

Active auditory stimulation group: Participants complete digital CogT and use the headband during sleep with active PTAS intended to enhance deep sleep.

Sham stimulation group: Participants complete the same digital CogT and use the headband during sleep, but the sounds delivered do not provide targeted deep sleep stimulation (sham condition).

Neither participants nor study staff involved in assessments and trial conduct are aware of group allocation.

Study Procedures The intervention phase lasts 5 weeks and is performed primarily at home. Participants use the headband during sleep as often as possible throughout the 5-week period. Digital CogT is performed at home on a tablet during weeks 2-5 (total of 4 weeks), three sessions per week, approximately 50 minutes per session, with scheduling adapted to individual daily routines.

Participants attend study visits at University Hospital Zurich, including assessments before the intervention, after the 5-week intervention, and at a 3-month follow-up. These visits include approximately half a day of assessments and an overnight stay in the sleep laboratory. Assessments include standardized neuropsychological testing of cognitive performance, questionnaires addressing sleep-related symptoms, non-motor symptoms, and quality of life, and overnight recording of brain activity during sleep using high-density electroencephalography (hdEEG). Blood samples are collected to explore biomarkers that may reflect biological processes related to brain function. In addition, participants wear an actimeter (a watch-like activity monitor) for defined periods to capture activity patterns and sleep-wake behavior.

Prior to final enrollment, participants complete a familiarization phase at home (typically 1-5 nights) to assess tolerability of sleeping with the headband. Depending on prior clinical information, a one-night home sleep assessment may be performed to screen for relevant sleep disorders such as sleep apnea.

Outcome and Objectives - Overview The primary objective is to determine whether enhancement of deep sleep via PTAS increases the benefit of CogT on cognitive performance in people with PD and MCI. Secondary objectives include evaluating the effects of the combined intervention on sleep physiology (as assessed by hdEEG) and exploratory blood-based biomarkers.

The study is conducted in Switzerland in accordance with applicable legal and ethical requirements for research involving humans, including data protection regulations, and has been reviewed and authorized by the responsible ethics committee and Swissmedic. The study is planned as a national trial in Switzerland with approximately 50 participants. Participant data and samples are coded to protect confidentiality, and participation is voluntary; participants may withdraw at any time without consequences for their ongoing medical care.

03

Conditions studied

  • Parkinson's Disease
  • Mild Cognitive Impairment

Keywords

  • PD-MCI
  • Sleep
  • Parkinson's Disease
  • Neurodegeneration
  • Mild Cognitive Impairment
  • Cognitive Training
  • Digital Cognitive Training
  • Auditory Stimulation
  • Acoustic Stimulation
  • Randomized Clinical Trial
  • Wearable Device
  • Electroencephalography
  • Blood-based Biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical diagnosis of PD along the MDS criteria (Postuma et al., 2015)
  • MCI according to the MDS criteria, level I (Litvan et al., 2012):
  • - cognitive decline: Gradual decline, in the context of established PD, in cognitive ability reported by either the patient or informant, or observed by the clinician, AND
  • - ≤ 26 and ≥ 18 (Hoops et al., 2009)
  • stable home situation (e.g. long-term place to live) that allows for reliable application of intervention for the duration of the study
  • ability to apply the sleep intervention for the duration of study, either alone or with assistance of a co-habitant if needed
  • ability to apply the CogT intervention for the duration of study
  • sufficient German language comprehension to follow the study procedures and answer all questions related to the study outcomes
  • dosing of dopaminergic and other PD treatment must have been stable for at least 14 days prior to the intervention period and will be expected to remain stable until the end of the study.

Exclusion criteria

Exclusion Criteria:

Diagnosis/Comorbidities:

  • clinical diagnosis of dementia (cognitive impairment sufficient to interfere with independence in everyday activities, i.e. "major neurocognitive disorder", )
  • known presence of neurologic (other than PD) or psychiatric disorder
  • Parkinsonism without response to levodopa; atypical Parkinsonian syndromes as assessed from medical history and clinical examination
  • severe medical conditions (for example, renal insufficiency, liver failure, or congestive heart failure) as assessed in the semi-structured screening interview
  • regular use of benzodiazepines and other central nervous system (CNS)-depressant substances as assessed in the semi-structured screening interview
  • known or suspected drug- or medication abuse as assessed in the semi-structured screening interview
  • substance or alcohol abuse (i.e. > 0.5 l wine or 1 l beer per day) as assessed in the semi-structured screening interview

Sleep disorders that could interfere with the sleep intervention:

  • obstructive sleep apnea with apnea-hypopnea index (AHI)>15, apnea-related NREM sleep fragmentation, and indication for treatment (in turn, primarily REM-related sleep apnea, not requiring specific treatment may be considered eligible); or use of continuous positive airway pressure (CPAP)
  • Restless Legs Syndrome
  • frequent (i.e. weekly) Non-REM sleep parasomnia (Sleep disorders typically associated with PD will not lead to exclusion, i.e. REM sleep behavior disorder, insomnia, nocturnal PD symptoms.)

PTAS:

  • inability to hear the tones produced by the sleep headband (TOSOO Axora device)
  • non-responder to PTAS during screening (PTAS does not evoke a discernable auditory evoked potential AEP)
  • skin disorders/problems/allergies in face/ear area that could worsen with electrode application
  • known or suspected non-compliance

Cognition \& :

  • inability to follow the procedures of the study, e.g. due to language problems, cognitive deficits
  • failure to give informed consent

Other studies:

  • participation in another study with interventions within 30 days (PTAS) or 1 year (CogT) preceding and during the present study
  • previous enrolment in the current study
  • enrolment of the investigator, his/her family members, employees and other dependent persons

Special events / behavior with impact on circadian rhythm, sleep, or cognition:

  • shift work (work during the night)
  • travelling more than 2 time zones in the last month before intervention starts or during intervention (start of intervention will be adapted to fit with this criteria)
  • planned medical intervention of substantial relevance, e.g. surgery, during intervention (routine assessments, e.g. check-ups will be allowed)

Pregnancy:

  • women who are pregnant or breastfeeding,
  • intention to become pregnant during the course of the study,
  • lack of safe , defined as: Female participants of , not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Please note that female participants who are surgically sterilized/hysterectomized or for longer than 1 year are not considered as being of child bearing potential.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    PTAS + Digital Cognitive Training

    Participants in this arm will receive active phase-targeted auditory stimulation during sleep. In addition, all participants will complete an identical digital, home-based cognitive training program following the same study schedule and procedures.

    Device: Phase-Targeted Auditory Stimulation (PTAS) · Other: Digital Cognitive Training (CogT)

  • Sham comparator
    Sham-PTAS + Digital Cognitive Training

    Participants in this control arm will receive sham PTAS using the same device and identical procedures as in the active condition, but without inducing slow-wave enhancement. All participants will also complete the same digital, home-based cognitive training program.

    Other: Digital Cognitive Training (CogT)

Interventions

  • DevicePhase-Targeted Auditory Stimulation (PTAS)

    Participants will receive Phase-Targeted Auditory Stimulation (PTAS) during sleep delivered via a wearable device to enhance slow-wave activity in sleep.

  • OtherDigital Cognitive Training (CogT)

    All participants will complete a digital, home-based cognitive training (CogT) program following a standardized schedule.

06

What researchers measure

Primary outcomes

  1. Additive Effect of PTAS on Cognitive Improvements (Executive Performance) Through Digital Cognitive Training in PD-MCI

    The primary outcome is the change in executive functioning between baseline and follow-up assessments, compared between the CogT+PTAS and CogT+Sham groups. Executive performance will be measured using an equally weighted composite domain score, calculated as the mean of multiple demographically adjusted, standardized z-scores from neuropsychological tests within the executive domain. This composite score captures the multidimensional nature of executive functions and reduces random measurement error.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

Secondary outcomes

  1. Additive Effect of PTAS on Cognitive Improvements (Global Cognitive Performance) Through Digital Cognitive Training in PD-MCI

    Secondary outcomes include the change in global cognition between baseline and follow-up assessments, compared between the CogT+PTAS and CogT+Sham groups. Global cognition will be measured using an equally weighted composite score across multiple cognitive domains, based on standardized and demographically adjusted neuropsychological test results.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

  2. Additive Effect of PTAS on Cognitive Improvements (Attention and Working Memory) Through Digital Cognitive Training in PD-MCI

    Change in attention and working memory performance will be compared between groups across time. This domain will be assessed using an equally weighted composite score, calculated from standardized z-scores of multiple neuropsychological tests within the attention and working memory domain.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

  3. Additive Effect of PTAS on Cognitive Improvements (Visuo-Cognitive Performance) Through Digital Cognitive Training in PD-MCI

    Secondary analyses will assess group differences in changes in visuo-cognitive abilities across time. Visuo-cognition will be captured using an equally weighted composite domain score based on standardized z-scores from relevant neuropsychological tests.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

  4. Additive Effect of PTAS on Cognitive Improvements (Language Performance) Through Digital Cognitive Training in PD-MCI

    Changes in language function will be compared between the intervention groups from baseline to follow-up. Language outcomes will be assessed using an equally weighted composite score derived from standardized test performance in the language domain.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

  5. Effect of PTAS on Blood Neurofilament Light Chain (NfL) Levels in PD-MCI

    Blood levels of neurofilament light chain (NfL), a biomarker of neurodegeneration and future cognitive decline, will be measured to assess potential additive effects of PTAS compared to sham stimulation. Blood samples will be collected under fasting conditions during clinical visits and analyzed for changes between groups over time.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

Other outcomes

  1. Change in Subjective Cognitive Decline (SCD)

    Exploratory analyses will assess changes in subjective cognitive decline (SCD) between baseline and follow-up assessments, comparing the CogT+PTAS and CogT+Sham groups. SCD will be measured using standardized self-report questionnaires.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

  2. Change in Quality of Life

    Changes in quality of life will be explored as an additional outcome comparing both intervention groups across time. Quality of life will be assessed using validated questionnaires completed during or shortly after clinical visits.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

  3. Exploratory Effect of PTAS on Non-Motor Symptoms in PD-MCI

    Exploratory outcomes include changes in selected non-motor symptoms, such as fatigue, depressive symptoms, sleep disturbances, and daytime sleepiness. Group differences between CogT+PTAS and CogT+Sham will be evaluated using standardized rating scales.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

  4. Change in Vigilance and Inhibitory Control

    Exploratory analyses will examine whether PTAS has additive effects on vigilance and inhibitory control, assessed through neuropsychological measures comparing changes between the two study groups over time.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

  5. Change in Blood Biomarkers Other Than NfL

    Exploratory biomarker outcomes include changes in additional blood-based markers related to neurodegeneration and neuroinflammation (e.g., α-synuclein, β-amyloid40/42, tau, phospho-tau, inflammatory markers). Blood samples will be collected during clinical visits to explore potential additive effects of PTAS compared to sham stimulation.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

  6. Change in Frontal Sleep EEG Markers Derived From the Sleep Device

    Exploratory analyses will assess changes in frontal sleep EEG markers derived from the wearable sleep device used during the intervention. These measures will be compared between groups to evaluate potential effects of PTAS on sleep physiology.

    Time frame: Assessed nightly during the intervention period between baseline (pre-intervention) and after 5 weeks (post-intervention)

  7. Change in Local Sleep EEG Markers Assessed With High-Density EEG (hdEEG)

    Exploratory outcomes include changes in local sleep EEG features, such as slow-wave activity (SWA), assessed using high-density EEG (hdEEG) during clinical visits. This allows evaluation of sleep-related neurophysiological effects beyond those captured by the wearable device.

    Time frame: Assessed at baseline (pre-intervention), after 5 weeks (post-intervention), and 3-month follow-up.

  8. Change in Physical Activity and Circadian Rhythm Parameters (Actigraphy)

    Exploratory analyses will investigate changes in physical activity levels and circadian rhythm patterns, derived from remote actigraphy recordings. Outcomes will be compared between groups to assess potential broader effects of PTAS on daily functioning and sleep-wake regulation.

    Time frame: Assessed continuously during the study and evaluated at baseline, post-intervention, and 3-month follow-up.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 20 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Mar 2, 2026
StartActual
Apr 22, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07441915
Collaborators
University Hospital, Zürich
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Apr 22, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 30, 2026

Study contacts

Simon J. Schreiner, MD
Contact
simon.schreiner@usz.ch
+41 43 253 24 18
Marie Therese Kleinsorge, MD
Contact
marie.kleinsorge@usz.ch
+41 43 253 13 10
Simon J. Schreiner, MD
principal investigator · University Hospital Zurich, University of Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion